The DT Clinical Trial Digital Tracker Survey indicates many trial professionals often are hesitant to dive fully into digital technology integration.
DT Consulting has released its inaugural Clinical Trial Digital Tracker Survey, designed to assess industry attitudes about digital adoption by global trial sites. According to the findings, many site professionals are reluctant to integrate digital tech into their process, citing factors like cost, complexity and selecting the appropriate tech for the job as the primary barriers.
The survey was crafted to determine the number of active research sites using digital technologies, what tools are employed, which digital tech they feel delivers the best results, and the obstacles sites and sponsors must overcome in integrating digital into their traditional operating models. DT Consulting sent the survey to all global interventional studies launched from October 2019 to September 2020 (six months before the COV
Thermo Fisher Scientific expands DTP trial service offerings
(ADragan/iStock via Getty Images Plus) The direct-to-patient service is designed to support trials and help to minimize trial length and costs, while boosting enrollment and participation rates.
Thermo Fisher Scientific has expanded its direct-to-patient (DTP) service offerings. The range now includes clinical site-to-patient, pharmacy-to-patient, and depot-to-patient services, so that patients can receive medication and supplies directly to their homes.
The DTP service builds on Thermo Fisher Scientific’s clinical site-to-patient offering that launched earlier in 2020, designed to make sure trial participants have access to life-saving investigational drug shipments with no need to travel to a clinic. The services are available in 47 different countries.
ObvioHealth announces upgraded decentralized trial platform The company’s technology facilitates remote patient monitoring and integrates with a wide range of wearable sensors for checking patient vital signs.
ObvioHealth has introduced a new platform that enables advanced remote-patient monitoring capabilities for decentralized trial solutions. The company’s decentralized platform and patient-centric smartphone app are designed to help create an ‘ecosystem’ of technology and devices approved by the US Food and Drug Administration (FDA) to support remote monitoring and patient connections with the help of the app.
Through partnerships with other companies like BioIntelliSense, AliveCor and iHealth, trial teams can remotely monitor up to 20 different vital signs, such as heart rate, respiratory rate, temperature, blood pressure, oxygen saturation, ECG, coughing episodes, sweat, sleep, activity levels and body positioning. Data from the devices is
A leader from Vocalis Health explains how health data can be culled from patient voice recordings to screen and monitor COVID-19 and other conditions.
OSP: Could you please share the ‘elevator presentation’ description of Vocalis who you are, what you do, and what sets you apart?
SH: Vocalis Health is an AI health tech company pioneering the development of vocal biomarkers – where health-related information is derived from analysis of people’s voice recordings – to screen, detect, monitor and predict health symptoms, conditions and diseases.
In 2016, I co-founded Vocalis Health with Daniel Aronovich, chief technical officer of the company. While treating patients in the hospital, I realized that I was habitually listening to their voices to gauge the state of their health.
According to Noxopharm, a recent study shows combining its Veyonda drug and a radiopharmaceutical yields favorable results against prostate cancer.
Noxopharm has released the most recent survival data from its LuPIN prostate cancer study. The company reports results show a median overall survival (mOS) of 19.7 months, higher than all other mOS results for existing prostate cancer treatments in their own registration studies.
These findings reportedly support evidence that a combination of Veyonda (NOX66) and experimental radiopharmaceutical 177lutetium-PSMA-617 could be successful in the treatment of metastatic castrate-resistant prostate cancer (mCRPC). This could offer a patient with mCRPC a high chance of the cancer responding to treatment to the extent of obtaining a meaningful survival outcome.